@FierceBiotech: Alzheimer's expert claims he was wooed into biotech insider scandal. Article | Follow @FierceBiotech
@JohnCFierce: First Pfizer, now J&J. Jim Allison is a big draw. Industry giants join MD Anderson's star team for immunotherapies. Story | Follow @JohnCFierce
@DamianFierce: If Amarin's latest Vascepa appeal fails, it has two more FDA rungs to climb, agency says. More | Follow @DamianFierce
@EmilyMFierce: Cleveland Clinic researchers find protein responsible for amyloid buildup, memory loss in Alzheimer's. Story | Follow @EmilyMFierce
> India's Biocon and Mylan ($MYL) have won approval for a biosimilar of Herceptin and plan to launch it in the subcontinent next month. Story
> Dicerna Pharmaceuticals has set its terms, laying out plans to sell 5 million shares for $11 to $13 a share. Story
> Durham, NC-based Argos Therapeutics is looking to raise about $60 million from the sale of 4.1 million shares in an IPO priced at $13 to $15 a share. Report
> NephroGenex has set terms for its IPO, planning to sell 3.1 million shares at $12 to $14 a share. At the mid-range the offering would raise about $40 million. Story
@FierceMedDev: J&J's Q4 looked great for orthopedics, but less so for diabetes and Dx. More | Follow @FierceMedDev
@MarkHFierce: Covidien said slow market growth led to its decision to abandon a renal denervation program. Story | Follow @MarkHFierce
@MichaelGFierce: Myriad will sell breast cancer Dx from Siemens spinoff in Europe. Item | Follow @MichaelGFierce
@EmilyWFierce: Boston physician questions medical devices used during minimally invasive hysterectomies. Article | Follow @EmilyWFierce
> Tandem expands its voluntary recall of the t:slim insulin pump. Report
> Medtronic's transcatheter heart valve scores early FDA approval. News
Pharma News
@FiercePharma: Saline shortage: FDA works with Baxter, Hospira and Braun. More | Follow @FiercePharma
@TracyStaton: J&J, Glaxo tops in pharma social media, but smaller companies rate highly, too. Report | Follow @TracyStaton
@EricPFierce: Roche says in an email that the temporary shortage of Tamiflu is over. The FDA says so too. More | Follow @EricPFierce
@CarlyHFierce: Forest's Q3 numbers are out - take a look. Release | Follow @CarlyHFierce
> Turbocharged pharma growth drives J&J's 2013 sales to $71B. Report
> Novartis to cut 500 Swiss pharma jobs, then staff up in OTC, generics. News
> NuPathe nixes Endo's buyout offer to hook up with Teva. Story
Pharma Manufacturing News
> Shire has a partially built plant for sale after unloading Dermagraft. News
> Aurobindo deal with Actavis accelerates its expansion of sterile injectables biz. Story
> FDA recall questions the sterility of eye drops made in Vietnam. Report
> Saline shortage: FDA works with Baxter, Hospira and Braun. More
> Genentech resolves plant backup quickly but timing was bad. Article
> Novartis manufacturing gets more jobs in major restructuring. Item
Biotech Research News
> Omnibus bill to restore $1B in funding to NIH. Story
> Microparticle therapy restores damaged tissue after a heart attack. Report
> AstraZeneca, Bristol-Myers bestow $5M on diabetes research program. Item
> Existing antiviral drug could treat H7N9 flu. Article
> Innovimmune inhibitor prevents multiple sclerosis in mice. More
> Alzheimer's research blames a protein for amyloid buildup, memory loss. News
CRO News
> Patheon soars in its last year as a public CMO. Item
> AMRI: Burlington 'money pit' is now a springboard. More
> Device CRO NAMSA rolls into the U.K. with Medvance buyout. Article
> Harlan targets India with latest animal model expansion. Story
> Parexel ups its expectations after a late-year stumble. Report
> BioClinica preps for another merger as CRO consolidation marches on. Article
Biotech IT News
> Record year at PLOS ONE creates new challenges for data scientists. Item
> Regeneron to sequence 100K exomes and link data to EHRs to speed drug discovery. Story
> BioClinica to go through second merger since being taken private last year. More
> European Union makes $40M available for development of bioinformatics tools. Article
> Illumina hits the $1,000 genome mark with a big-data 'cannonball.' Story
> FDA publishes a slice of social media guidance as the deadline for a full policy nears. Report